What is the optimal first‑line treatment for a 62‑year‑old woman with diabetes mellitus, obesity, chronic myeloid leukemia presenting with leukocytosis (white blood cell count 16,000/µL) and splenomegaly?

First-Line Treatment: Tyrosine Kinase Inhibitor Selection

For this 62-year-old woman with diabetes mellitus, obesity, and newly diagnosed chronic phase CML (WBC 16,000/µL with splenomegaly), imatinib 400 mg daily is the optimal first-line treatment, avoiding nilotinib due to her diabetes and cardiovascular risk factors. 1

Rationale for TKI Selection

Why Imatinib is Preferred in This Patient

Nilotinib must be avoided in this patient due to her diabetes mellitus and obesity. The 2017 ESMO guidelines explicitly state that nilotinib has been associated with hyperglycemia and should be used with caution in patients with uncontrolled diabetes 1. More critically, nilotinib carries significant risk of vaso-occlusive and vaso-spastic vascular events (ischemic heart disease, cerebrovascular events, peripheral arterial disease), and should be prescribed with caution in patients with diabetes or cardiovascular risk factors 1. Obesity and diabetes are established cardiovascular risk factors that substantially increase this patient's baseline risk.

Dasatinib should also be avoided given her obesity. Obese patients and those with hypertension are at increased risk for pleural effusion with dasatinib 2. While dasatinib 100 mg daily is an approved first-line option, the risk-benefit profile is less favorable in this patient.

Imatinib 400 mg daily remains the safest choice for this patient with multiple comorbidities. The 2020 and 2025 European LeukemiaNet recommendations confirm that all three first-line TKIs (imatinib, nilotinib, dasatinib) provide similar overall survival 3, 4. The key differentiator is the side-effect profile matched to patient comorbidities.

Treatment Initiation and Monitoring

Starting Treatment

• Begin imatinib 400 mg once daily immediately after BCR-ABL1 confirmation 1, 5
• Take with food and a large glass of water to minimize GI upset 2
• Ensure adequate hydration (2.5-3 L fluid intake daily) to prevent tumor lysis syndrome 1
• Taper hydroxyurea before discontinuation if used for initial cytoreduction 1

Baseline Workup Required

Before starting therapy, obtain 5:

• Complete blood counts with differential
• Bone marrow cytology and karyotype (chromosome banding analysis)
• Qualitative RT-PCR for BCR-ABL1 transcript type identification
• Baseline ECG (all TKIs may prolong QT interval)
• Correct electrolyte abnormalities (potassium, magnesium) before starting 1

Monitoring Schedule

Hematologic monitoring:

• CBC with differential every 2 weeks until complete hematologic response achieved 3, 4
• Complete hematologic response defined as: WBC <10 × 10⁹/L, no immature granulocytes, basophils <5%, platelets <450 × 10⁹/L, non-palpable spleen 5

Molecular monitoring:

• Quantitative RT-PCR (BCR-ABL1% on International Scale) every 3 months 5, 3
• Bone marrow cytogenetics at 3,6, and 12 months, then every 6 months until complete cytogenetic response 5

Response Milestones and Treatment Adjustments

Optimal Response Criteria

At specific timepoints, the patient should achieve 3, 4:

• 3 months: BCR-ABL1 ≤10% (early molecular response)
• 6 months: BCR-ABL1 ≤1% (equivalent to complete cytogenetic response)
• 12 months: BCR-ABL1 ≤0.1% (major molecular response/MMR)

Managing Treatment Failure

If the patient fails to meet these milestones 5:

• Evaluate compliance first (critical step often overlooked)
• Perform BCR-ABL1 kinase domain mutation testing
• Switch to dasatinib 100 mg daily (second-line, avoiding nilotinib due to diabetes)
• Consider allogeneic stem cell transplant only after failure of two TKIs

Managing Imatinib-Specific Toxicities

Hematologic Toxicity

Grade 3-4 neutropenia (ANC <1000/mm³): 2

• Hold imatinib until ANC ≥1500/mm³
• Resume at 400 mg daily
• If recurrent, hold until ANC ≥1500/mm³, then resume at 300 mg daily
• Growth factors can be used for resistant neutropenia

Grade 3-4 thrombocytopenia (platelets <50,000/mm³): 2

• Hold until platelets ≥75,000/mm³
• Resume at 400 mg daily
• If recurrent, hold until platelets ≥75,000/mm³, then resume at 300 mg daily

Non-Hematologic Toxicity

Common manageable side effects 2:

• Edema/fluid retention: Diuretics, supportive care
• Muscle cramps: Calcium supplementation, tonic water
• GI upset: Take with meals and large glass of water
• Rash: Topical or systemic steroids; dose reduction if severe

Critical Pitfalls to Avoid

1. Do not use nilotinib in this patient - The combination of diabetes and obesity creates unacceptable cardiovascular risk 1

2. Do not delay treatment - Start TKI immediately after BCR-ABL1 confirmation; delays worsen outcomes 1

3. Do not skip mutation testing at failure - BCR-ABL1 kinase domain mutations guide second-line TKI selection 5

4. Do not ignore rising BCR-ABL1 transcripts - A 1-log increase warrants immediate evaluation for compliance and consideration of bone marrow cytogenetics 2

5. Monitor diabetes control closely - While imatinib is safer than nilotinib, ensure optimal glycemic management throughout treatment

Expected Outcomes

With imatinib 400 mg daily, this patient can expect 3:

• Early molecular response (BCR-ABL1 ≤10%) in 60-80% at 3-6 months
• Major molecular response in 20-59% at 1 year
• Overall survival approaching that of age-matched controls
• Normal life expectancy if optimal response achieved

The presence of splenomegaly and WBC 16,000/µL indicates chronic phase disease requiring standard-dose imatinib, not high-dose therapy 5, 6.